Razuprotafib (AKB-9778) 是 VE-PTP (HPTPß) 催化活性的有效选择性抑制剂 (IC₅₀=17 pM)，促进 TIE2 活化，增强 ANG1 诱导的 TIE2 活化，并刺激 TIE2 通路中信号分子的磷酸化，包括 AKT、eNOS 和 ERK。Razuprotafib 抑制结构相关磷酸酶 PTP1B，IC₅₀ 为 780 nM。除 HPTPη (IC₅₀=36 pM) 和 HPTPγ (100 pM) 外，Razuprotafib 对 VE-PTP 具有良好的选择性。

Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC 50 of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC 50 of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC 50 =36 pM) and HPTPγ (100 pM).

Solid

Razuprotafib (AKB-9778) promotes TIE2 phosphorylation and activation of downstream signaling in HUVECs and enhances angiopoietin-induced TIE2 phosphorylation. has not independently confirmed the accuracy of these methods. They are for reference only.

Razuprotafib (20 mg/kg; s.c.) promotes phosphorylation of TIE2 in retinal endothelial cells in vivo. Razuprotafib (10-20 mg/kg; s.c.; twice daily for 7 days) suppresses subretinal neovascularization (NV). has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Shen J, et al. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest. 2014;124(10):4564-4576.

In Vitro: DMSO : 100 mg/mL (170.44 mM; Need ultrasonic)配制储备液